NEW YORK, May 9, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NewLink Genetics Corporation ("NewLink" or the "Company") (NASDAQ: NLNK). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 237.
The investigation concerns whether NewLink and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On May 9, 2016, post-market, NewLink announced that the Company's experimental pancreatic cancer immunotherapy algenpantucel-L did not meet the main goal in a late-stage study. Patients treated with algenpantucel-L lived for a median of 27.3 months in NewLink's phase III trial, compared to median survival of 30.4 months for patients treated with standard therapy, suggesting that patients might have actually been harmed by NewLink's treatment.
On this news, NewLink's stock price has fallen as much as $6.36, or 38.48%, to $10.15 after-hours on May 9, 2016.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-newlink-genetics-corporation---nlnk-300265329.html
SOURCE Pomerantz LLP